https://www.thebodypro.com/author/myles-helfand
Myles Helfand Img

Myles Helfand

Executive Editor

Myles is the executive editor and general manager of TheBody/TheBodyPro. A career journalist and editor, Myles joined TheBody in 2001 as a part-time copyeditor. He has since established himself as a leading journalist and content strategist on HIV-related issues, authoring hundreds of articles and editing hundreds more -- and accumulating an ever-growing mountain of HIV conference badges along the way.

Latest by Myles Helfand

silver linings
News

This Week in HIV Research: In Every Cloud, a Silver Lining

April 2, 2020: Physical activity vs. heart med adherence; reducing the burden of HIV emergency care; increasing smoking cessation intervention success; virologic failure following asymptomatic HIV treatment initiation.

lab testing
News

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

staying in touch
Conference Coverage

Coronavirus (COVID-19): What the HHS and CDC Are Recommending to HIV/AIDS Clinicians

Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.

beat goes on
Research

This Week in HIV Research: The Beat Goes On

March 19, 2020: Mood disorders and metabolic syndrome; comorbidity burden among women living with HIV; two-year weight gain after switching to integrase; long-term adipose tissue density trends.

coronary atherosclerosis
Conference Coverage

Recent Initiation of Testosterone Therapy Linked to Greater Atherosclerosis Progression in MSM With HIV

New findings contribute to the indication that people with HIV taking testosterone therapy should be counseled on the cardiovascular risks.

birthday candles
News Analysis

HIV Life Expectancy in U.S. Now Matches General Population—With Some Big “Buts”

The biggest may be that more of an HIV-positive person’s equally long lifespan will be spent managing comorbidities, one large study found.

aging face
Research

This Week in HIV Research: Playing Catchup on the Aging Front

March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.

pill bottles and cash
Conference Coverage

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

virology
News

This Week in HIV Research: Is Viral Suppression an STI Prevention Tool?

March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.

men on beach
News

This Week in HIV Research: Do You Believe in U=U?

Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.